AnaptysBio (ANAB) PT Raised to $147 at Credit Suisse
Tweet Send to a Friend
Credit Suisse analyst Martin Auster raised the price target on AnaptysBio (NASDAQ: ANAB) to $147.00 (from $104.00) while maintaining an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
